Angiogenesis and especially, VEGF-A have become attractive pharmacologic targets in colorectal cancer (CRC), which is the third most common cancer in males and the second in females; only in 2015, 1.65 million new CRC cases and almost 835,000 deaths were recorded [14]. This evidence concerns the gene VEGFA and colorectal carcinoma.